Publications by authors named "S Alper Toker"
Although metallic implants provide most of the required properties for bone-related applications, especially orthopedic implants, insufficient osseointegration, which may lead to loosening of the implant or prolonged healing time, is still an issue to be resolved. Osseointegration can be improved via application of various surface treatments on the metal surface. The current study focuses on a novel surface microdeformation method, which enables the formation of controlled surface patterns of various parameters.
View Article and Find Full Text PDFBreast and gynecologic cancers are common across the world and are associated with substantial societal and economic burden. Pembrolizumab was among the first immune checkpoint inhibitors targeting programmed cell death protein 1 to be approved for the treatment of patients with triple-negative breast cancer, cervical cancer, and endometrial cancer. Recent clinical trials have established pembrolizumab regimens as a standard of care treatment for these tumor types.
View Article and Find Full Text PDFArticle Synopsis
- - In the KEYNOTE-826 study, pembrolizumab combined with chemotherapy significantly boosted overall survival (OS) and progression-free survival (PFS) in patients with advanced cervical cancer, with specific attention to those using bevacizumab.
- - The analysis included 617 patients, with a majority excluded from bevacizumab due to medical reasons; outcomes showed that those receiving pembrolizumab generally had better survival metrics, regardless of bevacizumab use.
- - Patients on pembrolizumab experienced a high rate of severe side effects, with 74% suffering grade ≥3 treatment-related adverse events in the bevacizumab group.
Article Synopsis
- - The phase 3 study ENGOT-cx11/GOG-3047/KEYNOTE-A18 found that adding pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival in patients with advanced cervical cancer during the first interim analysis.
- - In this study, 1060 patients with high-risk cervical cancer were randomly assigned to receive either pembrolizumab or a placebo alongside chemoradiotherapy, with treatment outcomes evaluated at the second interim analysis.
- - The primary outcomes measured were progression-free survival and overall survival, focusing on patient mortality, with safety being a secondary consideration.
Hypertension is present in almost a third of Türkiye's adult population. The Ministry of Health of the Republic of Türkiye in conjunction with the World Health Organization, rolled out a pilot primary health care model from February 2019 to 2020 to improve hypertension screening, management, and follow-up across the provinces of Erzincan, Çankırı and Uşak. The model was conducted in selected family health centers for one year and included multiple interventions - training of multidisciplinary primary care teams, implementation of evidence-based, standardised clinical guidelines related to monitoring and treatment of hypertension, clinical supervision and performance monitoring, and provision of health education to hypertensive individuals.
View Article and Find Full Text PDF